See more : Arway Corporation (ARWYF) Income Statement Analysis – Financial Results
Complete financial analysis of PeptiDream Inc. (4587.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PeptiDream Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- GenIP Plc (GNIP.L) Income Statement Analysis – Financial Results
- IMV Inc. (IMVIQ) Income Statement Analysis – Financial Results
- Mingfa Group (International) Company Limited (0846.HK) Income Statement Analysis – Financial Results
- Coast Copper Corp. (COCCF) Income Statement Analysis – Financial Results
- Nordon Indústrias Metalúrgicas S/A (NORD3.SA) Income Statement Analysis – Financial Results
PeptiDream Inc. (4587.T)
About PeptiDream Inc.
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.71B | 26.85B | 9.37B | 11.68B | 2.07B | 7.22B | 6.43B | 4.90B | 4.33B | 2.47B | 818.90M | 678.27M | 269.00M |
| Cost of Revenue | 11.49B | 8.74B | 2.36B | 2.15B | 1.41B | 1.65B | 1.78B | 1.36B | 1.09B | 721.64M | 314.76M | 267.58M | 167.42M |
| Gross Profit | 17.22B | 18.11B | 7.01B | 9.53B | 661.06M | 5.57B | 4.65B | 3.54B | 3.24B | 1.75B | 504.14M | 410.69M | 101.58M |
| Gross Profit Ratio | 59.97% | 67.46% | 74.82% | 81.61% | 31.86% | 77.12% | 72.33% | 72.22% | 74.90% | 70.84% | 61.56% | 60.55% | 37.76% |
| Research & Development | 3.16B | 2.92B | 1.65B | 1.46B | 1.79B | 0.00 | 921.34M | 362.68M | 228.21M | 88.55M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.26B | 6.22B | 1.35B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.27B | -218.56M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.26B | 6.22B | 1.14B | 1.01B | 648.86M | 0.00 | 748.43M | 676.93M | 464.80M | 272.80M | 302.78M | 249.88M | 0.00 |
| Other Expenses | 34.11M | -2.44M | 2.59B | 2.54B | 0.00 | 1.99B | 1.74B | 1.05B | 1.51M | 200.00K | 345.00K | -14.66M | 7.99M |
| Operating Expenses | 10.45B | 9.13B | 2.59B | 2.54B | 2.44B | 1.99B | 1.74B | 1.05B | 693.51M | 361.73M | 302.78M | 249.88M | 119.75M |
| Cost & Expenses | 21.94B | 17.87B | 4.95B | 4.69B | 3.85B | 3.64B | 3.52B | 2.41B | 1.78B | 1.08B | 617.54M | 517.46M | 287.18M |
| Interest Income | 190.98M | 189.05M | 283.00K | 2.17M | 2.36M | 6.39M | 1.73M | 1.30M | 1.73M | 6.15M | 6.41M | 68.00K | 41.00K |
| Interest Expense | 2.25B | 2.31B | 30.00K | 0.00 | 90.00K | 4.24M | 1.71M | 188.77M | 695.00K | 90.00K | 29.62M | 3.38M | |
| Depreciation & Amortization | 2.43B | 1.97B | 633.01M | 571.02M | 512.54M | 521.48M | 513.34M | 194.87M | 143.00M | 103.06M | 73.74M | 52.37M | 41.55M |
| EBITDA | 9.24B | 9.02B | 5.01B | 7.56B | -1.26B | 4.10B | 3.42B | 2.69B | 2.69B | 1.49B | 275.10M | 213.18M | 23.38M |
| EBITDA Ratio | 32.20% | 40.74% | 53.41% | 72.95% | -60.82% | 56.83% | 53.32% | 54.86% | 62.33% | 60.51% | 33.59% | 31.43% | 8.69% |
| Operating Income | 6.77B | 8.98B | 4.42B | 6.99B | -1.77B | 3.58B | 2.91B | 2.49B | 2.55B | 1.39B | 201.36M | 160.81M | -18.17M |
| Operating Income Ratio | 23.59% | 33.44% | 47.17% | 59.87% | -85.52% | 49.60% | 45.29% | 50.87% | 58.88% | 56.22% | 24.59% | 23.71% | -6.76% |
| Total Other Income/Expenses | -2.42B | -2.33B | 309.90M | -971.30M | 361.26M | 227.07M | 240.75M | 133.74M | -182.27M | 102.25M | 20.63M | 13.31M | -3.38M |
| Income Before Tax | 4.35B | 6.65B | 4.82B | 6.02B | -1.41B | 3.81B | 3.15B | 2.62B | 2.37B | 1.49B | 221.99M | 174.12M | -21.55M |
| Income Before Tax Ratio | 15.16% | 24.78% | 51.50% | 51.55% | -68.11% | 52.75% | 49.04% | 53.60% | 54.66% | 60.35% | 27.11% | 25.67% | -8.01% |
| Income Tax Expense | 1.32B | -901.03M | 1.22B | 1.57B | -436.15M | 1.04B | 816.51M | 733.41M | 784.52M | 489.21M | 73.48M | 36.94M | -31.52M |
| Net Income | 3.04B | 7.55B | 3.61B | 4.45B | -976.93M | 2.77B | 2.34B | 1.89B | 1.58B | 1.00B | 148.51M | 137.18M | 9.97M |
| Net Income Ratio | 10.57% | 28.13% | 38.51% | 38.09% | -47.09% | 38.39% | 36.34% | 38.62% | 36.54% | 40.58% | 18.14% | 20.23% | 3.71% |
| EPS | 23.41 | 58.19 | 27.98 | 35.40 | -7.80 | 22.42 | 19.35 | 16.54 | 14.23 | 9.18 | 1.39 | 1.54 | 0.12 |
| EPS Diluted | 23.38 | 58.14 | 27.76 | 34.26 | -7.80 | 21.33 | 17.79 | 14.56 | 12.26 | 7.83 | 1.39 | 1.23 | 0.12 |
| Weighted Avg Shares Out | 129.70M | 129.83M | 128.90M | 125.67M | 125.17M | 123.56M | 120.66M | 114.29M | 111.15M | 109.38M | 107.14M | 89.05M | 85.60M |
| Weighted Avg Shares Out (Dil) | 129.84M | 129.94M | 129.93M | 129.84M | 125.17M | 129.87M | 131.27M | 129.86M | 128.98M | 128.25M | 107.14M | 111.30M | 85.60M |
Source: https://incomestatements.info
Category: Stock Reports